The global impact of dementia is an increasing area of concern and, according to the Alzheimer’s Disease International (ADI) World Alzheimer Report 2021, up to 90% of dementia patients in low- and middle-income countries are not diagnosed [1]. Approximately 57.4 million people all over the world are affected by dementia, and this number is expected to triple to 152.8 by 2050, with a female-to-male ratio of 1.67 [1]. In this regard, among the most common forms of dementia, 60–80% are caused by Alzheimer’s disease (AD) [2]. Although AD accounts for almost two-thirds of all cases, the incidence of other mixed forms of dementia (such as frontotemporal, Lewy body, etc.) is rising worldwide, making Alzheimer’s disease and related dementias (ADRD) a public health priority [3]. There is little doubt that AD is a multifactorial disease, which involves diverse pathogenic mechanisms and will probably require combinatorial therapies. Although many pathological hallmarks have been widely described, such as accumulation of amyloid-beta (Aβ) aggregates and tau-containing neurofibrillary tangles, the mechanism underlying proteotoxicity and its role in combination with other factors at different disease stages [4,5] requires further clarification. In fact, much more research is needed regarding a better definition of the dementia pathophysiology and to better understand the mechanism of action of natural products in disorders of neuronal pathways [6,7].

Basic, Translational, and Clinical Research on Dementia

Giacinto Bagetta;
2024-01-01

Abstract

The global impact of dementia is an increasing area of concern and, according to the Alzheimer’s Disease International (ADI) World Alzheimer Report 2021, up to 90% of dementia patients in low- and middle-income countries are not diagnosed [1]. Approximately 57.4 million people all over the world are affected by dementia, and this number is expected to triple to 152.8 by 2050, with a female-to-male ratio of 1.67 [1]. In this regard, among the most common forms of dementia, 60–80% are caused by Alzheimer’s disease (AD) [2]. Although AD accounts for almost two-thirds of all cases, the incidence of other mixed forms of dementia (such as frontotemporal, Lewy body, etc.) is rising worldwide, making Alzheimer’s disease and related dementias (ADRD) a public health priority [3]. There is little doubt that AD is a multifactorial disease, which involves diverse pathogenic mechanisms and will probably require combinatorial therapies. Although many pathological hallmarks have been widely described, such as accumulation of amyloid-beta (Aβ) aggregates and tau-containing neurofibrillary tangles, the mechanism underlying proteotoxicity and its role in combination with other factors at different disease stages [4,5] requires further clarification. In fact, much more research is needed regarding a better definition of the dementia pathophysiology and to better understand the mechanism of action of natural products in disorders of neuronal pathways [6,7].
2024
Alzheimer disease, Neuropsychiatric symptoms, pharmacotherapy
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11770/368038
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact